Document is current
Any future updates will be listed below
-
Authors
Smyczynska, Urszula
Rycerz, Aleksander
Kozlowska, Klaudia
Symecko, Heather
Brower, Jamie
Domchek, Susan M.
Elias, Kevin
Konstantinopoulos, Panagiotis
Apostolidou, Sophia
Menon, Usha
Fendler, Wojciech
Chowdhury, Dipanjan
-
Funding
Funding for this research was provided by:
The Gray Foundation
Medical Research Agency in Poland (2023/ABM/02/00009)
National Science Center Poland (2023/49/B/NZ5/03835)
National Science Center Poland (2023/49/B/NZ5/03835)
Breast Cancer Research Foundation
Komen Foundation
Developmental Research Program of the Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE
Massachusetts Life Sciences Center Bits to Bytes Program
Deborah and Robert First Family Fund
Honorable Tina Brozman Foundation
MRC CTU at UCL core funding (MC_UU_00004/01)
Cancer Research UK and The Eve Appeal
National Institutes of Health and the National Cancer Institute (1P50CA240243-01A1)
The Mighty Moose Foundation
The V Foundation
- License Information
-
More Information
Article History
Received: 8 August 2025
Accepted: 13 December 2025
First Online: 9 January 2026
Declarations
:
: Sample collection was approved by the following ethical committees: Institutional Review Board of Dana-Farber Cancer Institute (#13–325), Institutional Review Board of University of Pennsylvania (#816688), Eastern Multicentre Research Ethics Committee (97/5/007)), North of Scotland Research Ethics Committee 2 21/NS/0082. The study was conducted in accordance with the Declaration of Helsinki. Patients provided informed consent for use of their samples in research.
: Not applicable.
: KE, WF, and DC. are co-inventors of patent US201762444085P/EP3565903A1 (title “Circulating microRNA signatures for ovarian cancer”), which relates to the use of circulating miRNAs for ovarian cancer diagnosis. KE, WF, and DC acknowledge research funding from Aspira Women’s Health. KE reports research funding from Abcam, Inc. US, KE, WF and DC submitted a patent application entitled “Use of circulating microRNA profiles for identification of BRCA1 or BRCA2 mutations”, related to the BRCA mutations test referenced in this manuscript. UM and SA report personal consulting fees from Mercy BioAnalytics Ltd. and research grants paid to the institution from Intelligent Lab on Fiber, RNA Guardian, MercyBio Analytics and CleoDx related to early detection of cancer especially ovarian cancer. UM declares membership of the Research Advisory Panel, Yorkshire Cancer Research (UK) and honorarium for membership of Tina’s Wish Scientific Advisory Board (USA). UM holds patent number EP10178345.4 for Breast Cancer Diagnostics.The remaining authors declare no competing interests.
